“During the third quarter, our team continued to advance our portfolio while winding down activities surrounding the BEACON-IPF trial,” said Bernard Coulie, President and Chief Executive Officer of Pliant. “Looking ahead, we continue to evaluate a range of opportunities to create shareholder value.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLRX:
- Pliant Therapeutics Announces CBO Hans Hull’s Resignation
- Pliant Therapeutics Settles Loan with Oxford Finance
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Align downgraded, NetEase upgraded: Wall Street’s top analyst calls
- Pliant Therapeutics downgraded to Underweight from Neutral at JPMorgan